Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.70−0.05 (-6.48%)
Close on Nov 18, 2026Market cap $240.43MP/E –Yield 0.00%
Allogene Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Allogene Therapeutics's price to sales ratio was 14.7× on Jan 31, 2023, against 42.4× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 14.7× | +2.7 |
| 2022 | Dec 30, 2022 | 12.0× | −43.3 |
| 2021 | Dec 31, 2021 | 55.3× | – |
See a number that looks wrong?